To explore the effectiveness and safety of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy (NIPS) in treating gastric cancer patients with peritoneal metastasis.
 
  80 patients definitely diagnosed with peritoneal metastasis of gastric cancer treated in our hospital from March 2016 to September 2017 were evaluated. All the patients were randomly assigned into two groups and received oral administration of S-1 + intravenous and intraperitoneal chemotherapy with paclitaxel or oral administration of S-1 + intravenous chemotherapy with oxaliplatin, with 40 patients in each group. Following NIPS conversion therapy, the patients with indications for surgery underwent radical gastrectomy. The short-term efficacy of chemotherapy and incidence of chemotherapy-related adverse reactions were compared between the two groups. The surgical methods, intraoperative conditions (lymph node dissection and surgical margins) and postoperative complications were recorded in the two groups of patients, aival (mOS) was 13.4 months in NIPS group and 10.8 months in control group.
 
  NIPS combined with radical gastrectomy has definite efficacy in treating gastric cancer patients with peritoneal metastasis and cause tolerable adverse reactions, and it can significantly raise the patient survival compared with systemic chemotherapy alone.
 NIPS combined with radical gastrectomy has definite efficacy in treating gastric cancer patients with peritoneal metastasis and cause tolerable adverse reactions, and it can significantly raise the patient survival compared with systemic chemotherapy alone.
  Perioperative enteral nutrition supports are recommended in esophagus cancer patients.  https://www.selleckchem.com/products/trastuzumab.html  Immunonutrition contains immuno-enhancing nutrients in addition to standard formula. These new nutrients are thought to be efficacious in reducing inflammatory response and improving postoperative immune response and they have been proved to be better than standard enteral nutrition in reducing postoperative complications in gastric cancer. However, if it would lead to a better clinical outcome in patients undergoing esophagectomy remains controversial.
 
  A systematic literature search was performed in the online database of PubMed, Medline, EMBASE and Cochrane Library. The relevant studies were screened out of the results by reading titles and abstracts. Then, we read the full-texts to finally confirm the studies included in this meta-analysis.
 
  Six randomized controlled trials having enrolled 638 patients were included in the final analysis. The pooled analysis didn't show statistically significant difference between immunonutrition group and standard nutrition group in reducing postoperative complications.
 
  The postoperative complications are comparable between immunonutrition and the standard enteral nutrition in patients undergoing esophagectomy, but its value in severe malnutrition patients is undetermined, whereas the high tolerance and other advantages brought by the immunonutrition should not be overlooked and need to be further proved.
 The postoperative complications are comparable between immunonutrition and the standard enteral nutrition in patients undergoing esophagectomy, but its value in severe malnutrition patients is undetermined, whereas the high tolerance and other advantages brought by the immunonutrition should not be overlooked and need to be further proved.
  The purpose of this study was to compare the multifocal (MF)/multicentric (MC) breast cancers with unifocal (UF) breast cancers in terms of tumour characteristics, treatment methods, loco-regional recurrence and survival rates.
 
  Patients who were treated with a diagnosis of early-stage breast cancer (stage I,II) and had regular follow-up were included in the study. MF tumours were defined as having more than one tumour focus in the same quadrant, whereas MC tumours refered to the presence of more than one tumour focus in different quadrants.
 
  In total, 1865 patients with invasive breast cancer were evaluated, 1493 (80.1%) of whom had UF cancer, 330 (17.7%) had MF cancer, and 42 (2.3%) had MC cancer. After comparing the groups with each other, it was seen that MF and MC breast cancers occurred more often at early ages and that lymph node invasion (LNI) was greater. No differences were seen between the 3 groups in terms of local recurrence-free survival (RFS) and overall survival (OS) rates . In multivariate analysis, it was found that MF and MC tumours had no impact on local recurrence and OS. In multivariate analysis, it was understood that HER2 positivity and triple-negative breast cancer (TNBC) had an impact on local recurrence, and age, lymphovascular invasion (LVI), T3 tumour, lymph node positivity and TNBC subtype had an impact on OS.
 
  Although MC and MF tumours show aggressive features such as high lymph node positivity and LVI, they have similar loco-regional recurrence and survival rates to UF tumours.
 Although MC and MF tumours show aggressive features such as high lymph node positivity and LVI, they have similar loco-regional recurrence and survival rates to UF tumours.
  To explore the efficacy and safety of 500 mg of fulvestrant for the postmenopausal patients with estrogen receptor (ER)-positive metastatic breast cancer, and to analyze the factors affecting the prognosis of patients.
 
  A retrospective analysis was conducted on the clinical data of 86 postmenopausal patients with ER-positive metastatic breast cancer, who were admitted to our hospital from January 2015 to December 2016, and these patients were treated with 500 mg of fulvestrant. The clinical efficacy and incidence of adverse reactions were evaluated. Moreover, the patients were followed up for recording the survival and disease progression. Finally, survival analysis was carried out using the Kaplan-Meier method, log-rank test and Cox's proportional hazards regression model.
 
  Among the 86 patients, 7 achieved partial response (PR), with an objective response rate (ORR) of 8.1%, and 44 (51.2%) had stable disease (SD), including 21 cases of SD ≥24 weeks, and the clinical benefit rate (CBR) [proportion of cases of complete response (CR) + PR +SD ≥24 weeks] was 36.